Work

129 Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme

Year: 2012

Type: conference-abstract

Source: European Urology Supplements

DOI: 10.1016/s1569-9056(12)60128-6

Authors: A.K. Bahl, S. Masson, Z. Malik, A. Birtle, S. Sundar, R. Jones, N. James, M. Mason, S. Kumar, D. Bottomley, A. Lydon, S. Chowdhury, J. Wylie, J. De Bono

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559806461

Cites:

Cited by: 14

Related to: 10